The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2016 | CLL highlights from ASCO 2016: HELIOS trial, CAR T-cell therapy and CLL-IPI
John Pagel, MD, PhD of the Swedish Cancer Institute, Seattle, WA discusses highlights for chronic lymphocytic leukemia (CLL) from the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Dr Pagel talks about data on from the HELIOS trial of ibrutinib in combination with bendamustine and rituximab (EudraCT No. 2012-000600-15). Further, data around CAR T-cell therapy, which is promising, will be discussed at the meeting. Dr Pagel also mentions acalabrutinib, a second generation BTK inhibitor. Finally, he discusses the prognostication of patients and the CLL-IPI score, which will help predict how patients will do over time and group them into a low, intermediate, high-risk or very high-risk group.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
